Department of Internal Medicine

Infectious Diseases Faculty

Jack Stapleton photo

Medical School:
University of Kansas

Residency:
University of North Carolina

Fellowship:
University of North Carolina

Jack T. Stapleton, M.D.
Professor and Division Director
Director, University of Iowa HIV Program
Director, Helen C. Levitt Center for Viral Pathogenesis and Disease

As Director of the University of Iowa HIV clinic, Dr. Stapleton is dedicated to overseeing and providing excellent medical care for people infected with the human immunodeficiency virus (HIV) and/or hepatitis C virus (HCV).  His laboratory research focuses on the interactions between flaviviruses and HIV in vitro and in vivo.  This work originated as epidemiologic and laboratory studies of the effects of co-infection of GB virus type C (GBV-C, a human flavivirus) and HIV, and has expanded to include studies of several other flaviviruses including HCV, Dengue virus and Yellow Fever virus.  In addition, Dr. Stapleton has several clinical studies under way related vaccines (HPV, HSV, smallpox) and to the natural history, management and therapy of HIV, hepatitis C virus, and GBV-C.

Honors, Awards, and Organizations

Links of Interest

Publications

  1. Stapleton, J.T., Chaloner, K., Zhang, J., Klinzman, D., Souza, I.E., Xiang, J., Landay, A., Fahey, J., Pollard, R., Mitsuyasu, R. GB virus C viremia is associated with reduced CD4 expansion following interleukin 2 therapy in HIV-infected people receiving HAART. In Press. 2008.
  2. McLinden, J.H., Stapleton, J.T., Chang, Q., Xiang, J. Expression of the dengue virus type 2 NS5 protein in a CD4+ T cell line inhibits HIV replication. J Infect Dis. 198:860-863, 2008.
  3. Handelsman, E., Cheng, I., Thompson, B., Hershow, R., Mofenson, L.M., Hollinger, F.B., Chen, K.T., Burchett, S.K., Klinzman, D., Stapleton, J.T. and the Women and Infants Transmission Study Group (WITS). Impact of GB Virus type C Infection on Mother-to-Child HIV Transmission in the Women and Infants Transmission Study Cohort. HIV Medicine, 8:561- 567. 2007.
  4. McLinden, J.H., Kaufman, T.M., Xiang, J., Chang, Q., Klinzman, D., Engel, A.M., Hess, G., Schmidt, U., Houghton, M., Stapleton, J.T. Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding. J Virol, 80:12131-12140. 2006.
  5. Xiang, J., McLinden, J.H., Chang, Q., Kaufman, T.M., Stapleton, J.T. An 85 amino acid segment of the GB Virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T-cells. Proc Natl Acad Sci USA, 103:15570-15575, 2006.
  6. Wünschmann, S., Müller, H.M., Stipp, C.S., Hemler, M.E., Stapleton, J.T. In Vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs. J. Infect. Dis. 194:1058-1067, 2006.
  7. Xiang, J., George, S.L., Wünschmann, S., Chang, Q., Klinzman, D., Stapleton, J.T. GB virus C infection inhibits HIV-1 replication by increasing RANTES, MIP-1a, MIP-1b, and SDF-1. Lancet, 363:2040-2046, 2004.
  8. For additional publications, see PubMed.

Patents:

1994

United States Patent No. 5,294,548:  Recombinant Hepatitis A Virus Vaccine.  McLinden J, Rosen E, Winokur PL, Stapleton JT.

1998

United States Patent No. 5,846,735,  1998:  “Hepatitis C Virus Fc Binding Domain”  Stapleton, Han, Schmidt, and LaBrecque.

2005

United States Patent No. 6,870,043.  "Full-length GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4 positive T cells".  Xiang J, Wunschmann S, Schmidt WN, Stapleton JT. 

2007

United States Patent No. 7,291,723 “GB virus C and methods of treating viral infections”.  Stapleton JT, Xiang J, George SL.

Back to Infectious Diseases Faculty List